A new startup from one of the key scientists at Google DeepMind exits stealth today with $50 million in funding.
The versatility of biological products to treat disease never before considered has led numerous biopharmaceutical companies recently to announce expansions of production bioreactor capacity in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback